L
Li Chen
Researcher at Harvard University
Publications - 19
Citations - 2877
Li Chen is an academic researcher from Harvard University. The author has contributed to research in topics: Regulation of gene expression & TATA box. The author has an hindex of 13, co-authored 19 publications receiving 2450 citations. Previous affiliations of Li Chen include University of Vermont.
Papers
More filters
Journal ArticleDOI
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett,Elena J. Edelman,Sonja J. Heidorn,Christopher Greenman,Christopher Greenman,Anahita Dastur,King Wai Lau,Patricia Greninger,I. Richard Thompson,Xi Luo,Jorge Soares,Qingsong Liu,Francesco Iorio,Francesco Iorio,Didier Surdez,Li Chen,Randy J. Milano,Graham R. Bignell,Ah Ting Tam,Helen Davies,Jesse A. Stevenson,Syd Barthorpe,Stephen R. Lutz,Fiona Kogera,Karl P. Lawrence,Anne McLaren-Douglas,Xeni Mitropoulos,Tatiana Mironenko,Helen Thi,Laura Richardson,Wenjun Zhou,F Jewitt,Tinghu Zhang,Patrick O’Brien,Jessica L. Boisvert,Stacey Price,Wooyoung Hur,Wanjuan Yang,Xianming Deng,Adam Butler,Hwan Geun Choi,Jae Won Chang,José Baselga,Ivan Stamenkovic,Jeffrey A. Engelman,Sreenath V. Sharma,Sreenath V. Sharma,Olivier Delattre,Julio Saez-Rodriguez,Nathanael S. Gray,Jeffrey Settleman,P. Andrew Futreal,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Sridhar Ramaswamy,Ultan McDermott,Cyril H. Benes +57 more
TL;DR: It was found that mutated cancer genes were associated with cellular response to most currently available cancer drugs, and systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Journal ArticleDOI
hnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation.
Mary Lynch,Li Chen,Michael J. Ravitz,Sapna Mehtani,Kevin M. Korenblat,Michael J. Pazin,Emmett V. Schmidt +6 more
TL;DR: HnRNP K increased translation initiation, increased cell division, and promoted neoplastic transformation in an eIF4E-dependent manner, explaining how the 4EBE might replace TATA in the eif4E promoter.
Journal ArticleDOI
Lectin-Dependent Enhancement of Ebola Virus Infection via Soluble and Transmembrane C-type Lectin Receptors
Matthew Brudner,Marshall Karpel,Calli Lear,Li Chen,L. Michael Yantosca,Corinne Scully,Ashish Sarraju,Anna Sokolovska,M. Reza Zariffard,Damon P. Eisen,Bruce A. Mungall,Darrell N. Kotton,Amel Omari,I-Chueh Huang,Michael Farzan,Kazue Takahashi,Lynda M. Stuart,Gregory L. Stahl,Gregory L. Stahl,Alan Ezekowitz,Gregory T. Spear,Gene G. Olinger,Emmett V. Schmidt,Ian C. Michelow +23 more
TL;DR: It is demonstrated that MBL indeed enhances infection of Ebola, Hendra, Nipah and West Nile viruses in low complement conditions, and support the concept of an innate immune haplotype that represents critical interactions between MBL and complement component C4 genes and that may modify susceptibility or resistance to certain glycosylated pathogens.
Journal ArticleDOI
MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses.
Anna M Bruchez,Ky Sha,Joshua C. Johnson,Li Chen,Caroline Stefani,Hannah McConnell,Lea Gaucherand,Rachel Prins,Kenneth A. Matreyek,Adam J. Hume,Elke Mühlberger,Emmett V. Schmidt,Gene G. Olinger,Lynda M. Stuart,Lynda M. Stuart,Adam Lacy-Hulbert,Adam Lacy-Hulbert +16 more
TL;DR: The authors found that a transcription factor, major histocompatibility complex class II transactivator (CIITA) induces resistance in human cell lines by directing the expression of the p41 isoform of invariant chain (CD74), which inhibits viral entry by blocking cathepsin-mediated processing of the Ebola glycoprotein.
Journal ArticleDOI
Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
TL;DR: Uncommon ALK/ROS1/RET genomic breakpoint is an unreliable predictor of matched targeted therapy efficacy and functional validation by RNA or protein assay may add value for accurate detection and interpretation of rare fusions.